Preeclampsia — Prevention of Pre-eclampsia Using Metformin: a Randomized Control Trial
Citation(s)
Achen MG, Gad JM, Stacker SA, Wilks AF Placenta growth factor and vascular endothelial growth factor are co-expressed during early embryonic development. Growth Factors. 1997;15(1):69-80.
Butalia S, Gutierrez L, Lodha A, Aitken E, Zakariasen A, Donovan L Short- and long-term outcomes of metformin compared with insulin alone in pregnancy: a systematic review and meta-analysis. Diabet Med. 2017 Jan;34(1):27-36. doi: 10.1111/dme.13150. Epub 2016 Jun 8. Review.
De Leo V, Musacchio MC, Piomboni P, Di Sabatino A, Morgante G The administration of metformin during pregnancy reduces polycystic ovary syndrome related gestational complications. Eur J Obstet Gynecol Reprod Biol. 2011 Jul;157(1):63-6. doi: 10.1016/j.ejogrb.2011.03.024. Epub 2011 May 6.
Duckitt K, Harrington D Risk factors for pre-eclampsia at antenatal booking: systematic review of controlled studies. BMJ. 2005 Mar 12;330(7491):565. Epub 2005 Mar 2. Review.
Gathiram P, Moodley J Pre-eclampsia: its pathogenesis and pathophysiolgy. Cardiovasc J Afr. 2016 Mar-Apr;27(2):71-8. doi: 10.5830/CVJA-2016-009. Review.
Gilbert C, Valois M, Koren G Pregnancy outcome after first-trimester exposure to metformin: a meta-analysis. Fertil Steril. 2006 Sep;86(3):658-63. Epub 2006 Jul 31. Review.
Goldman-Wohl D, Yagel S Regulation of trophoblast invasion: from normal implantation to pre-eclampsia. Mol Cell Endocrinol. 2002 Feb 22;187(1-2):233-8. Review.
Gu Y, Lewis DF, Wang Y Placental productions and expressions of soluble endoglin, soluble fms-like tyrosine kinase receptor-1, and placental growth factor in normal and preeclamptic pregnancies. J Clin Endocrinol Metab. 2008 Jan;93(1):260-6. Epub 2007 Oct 23.
Lautatzis ME, Goulis DG, Vrontakis M Efficacy and safety of metformin during pregnancy in women with gestational diabetes mellitus or polycystic ovary syndrome: a systematic review. Metabolism. 2013 Nov;62(11):1522-34. doi: 10.1016/j.metabol.2013.06.006. Epub 2013 Jul 23. Review.
Li H, Gu B, Zhang Y, Lewis DF, Wang Y Hypoxia-induced increase in soluble Flt-1 production correlates with enhanced oxidative stress in trophoblast cells from the human placenta. Placenta. 2005 Feb-Mar;26(2-3):210-7.
Luttun A, Carmeliet P Soluble VEGF receptor Flt1: the elusive preeclampsia factor discovered? J Clin Invest. 2003 Mar;111(5):600-2.
Mostello D, Kallogjeri D, Tungsiripat R, Leet T Recurrence of preeclampsia: effects of gestational age at delivery of the first pregnancy, body mass index, paternity, and interval between births. Am J Obstet Gynecol. 2008 Jul;199(1):55.e1-7. doi: 10.1016/j.ajog.2007.11.058. Epub 2008 Feb 15.
Nagar T, Sharma D, Choudhary M, Khoiwal S, Nagar RP, Pandita A The Role of Uterine and Umbilical Arterial Doppler in High-risk Pregnancy: A Prospective Observational Study from India. Clin Med Insights Reprod Health. 2015 Apr 15;9:1-5. doi: 10.4137/CMRH.S24048. eCollection 2015.
Parker MW, Xu P, Li X, Vander Kooi CW Structural basis for selective vascular endothelial growth factor-A (VEGF-A) binding to neuropilin-1. J Biol Chem. 2012 Mar 30;287(14):11082-9. doi: 10.1074/jbc.M111.331140. Epub 2012 Feb 7.
Rena G, Hardie DG, Pearson ER The mechanisms of action of metformin. Diabetologia. 2017 Sep;60(9):1577-1585. doi: 10.1007/s00125-017-4342-z. Epub 2017 Aug 3. Review.
Ribatti D The discovery of the placental growth factor and its role in angiogenesis: a historical review. Angiogenesis. 2008;11(3):215-21. doi: 10.1007/s10456-008-9114-4. Epub 2008 Jun 21.
Simons M, Gordon E, Claesson-Welsh L Mechanisms and regulation of endothelial VEGF receptor signalling. Nat Rev Mol Cell Biol. 2016 Oct;17(10):611-25. doi: 10.1038/nrm.2016.87. Epub 2016 Jul 27. Review.
Skjaerven R, Wilcox AJ, Lie RT The interval between pregnancies and the risk of preeclampsia. N Engl J Med. 2002 Jan 3;346(1):33-8.
Tan X, Li S, Chang Y, Fang C, Liu H, Zhang X, Wang Y Effect of metformin treatment during pregnancy on women with PCOS: a systematic review and meta-analysis. Clin Invest Med. 2016 Sep 11;39(4):E120-31. Review.
Walsh SW What causes endothelial cell activation in preeclamptic women? Am J Pathol. 2006 Oct;169(4):1104-6.
Wang Y, Zhao S Vascular Biology of the Placenta. San Rafael (CA): Morgan & Claypool Life Sciences; 2010.
Wang Z, Wang P, Liu H, He X, Zhang J, Yan H, Xu D, Wang B Maternal adiposity as an independent risk factor for pre-eclampsia: a meta-analysis of prospective cohort studies. Obes Rev. 2013 Jun;14(6):508-21. doi: 10.1111/obr.12025. Epub 2013 Mar 26. Review.
Yusuf AM, Kahane A, Ray JG First and Second Trimester Serum sFlt-1/PlGF Ratio and Subsequent Preeclampsia: A Systematic Review. J Obstet Gynaecol Can. 2018 May;40(5):618-626. doi: 10.1016/j.jogc.2017.07.014. Epub 2017 Sep 15.
Zhao LP, Sheng XY, Zhou S, Yang T, Ma LY, Zhou Y, Cui YM Metformin versus insulin for gestational diabetes mellitus: a meta-analysis. Br J Clin Pharmacol. 2015 Nov;80(5):1224-34. doi: 10.1111/bcp.12672. Epub 2015 Jul 14. Review.
Zhao M, Zhu Z, Liu C, Zhang Z Dual-cutoff of sFlt-1/PlGF ratio in the stratification of preeclampsia: a systematic review and meta-analysis. Arch Gynecol Obstet. 2017 May;295(5):1079-1087. doi: 10.1007/s00404-017-4302-3. Epub 2017 Mar 17. Review.
Zheng J, Shan PF, Gu W The efficacy of metformin in pregnant women with polycystic ovary syndrome: a meta-analysis of clinical trials. J Endocrinol Invest. 2013 Nov;36(10):797-802. doi: 10.3275/8932. Epub 2013 Apr 12.
Zhu B, Zhang L, Fan YY, Wang L, Li XG, Liu T, Cao YS, Zhao ZG Metformin versus insulin in gestational diabetes mellitus: a meta-analysis of randomized clinical trials. Ir J Med Sci. 2016 May;185(2):371-81. doi: 10.1007/s11845-016-1414-x. Epub 2016 Feb 9.
Prevention of Pre-eclampsia Using Metformin: a Randomized Control Trial
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.